Fujiwara T, Inoue F, Tanaka N
First Department of Surgery, Okayama University Medical School.
Nihon Rinsho. 1997 May;55(5):1296-306.
Lung cancer is one of the leading causes of cancer death in the world. The high mortality rate for lung cancer results from the absence of standard therapeutic strategies. Recent advances in molecular biology have demonstrated that multistep genetic alterations are involved in the carcinogenesis of human lung cancer. Human gene therapy has become a reality with the development of effective techniques for delivering the gene to the target cells. The efficacy of gene therapy for various types of genetic disease now being evaluated in clinical trials. These findings led us to develop a novel gene therapeutic strategy for human lung cancer that could either inhibit the oncogene expression or replace the tumor suppressor gene by using recombinant, replication-defective viral vectors. The article reviews recent highlights in this rapidly evolving field.
肺癌是全球癌症死亡的主要原因之一。肺癌的高死亡率源于缺乏标准的治疗策略。分子生物学的最新进展表明，多步骤基因改变参与了人类肺癌的致癌过程。随着将基因传递到靶细胞的有效技术的发展，人类基因治疗已成为现实。基因治疗对各种类型遗传病的疗效目前正在临床试验中进行评估。这些发现促使我们开发一种针对人类肺癌的新型基因治疗策略，即通过使用重组的、复制缺陷型病毒载体来抑制癌基因表达或替代肿瘤抑制基因。本文综述了这一快速发展领域的最新亮点。
